Patents by Inventor AmirAli Talasaz

AmirAli Talasaz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250250639
    Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.
    Type: Application
    Filed: December 18, 2024
    Publication date: August 7, 2025
    Inventors: Stefanie Ann Ward MORTIMER, AmirAli TALASAZ, Darya CHUDOVA, Helmy ELTOUKHY
  • Publication number: 20250230495
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Application
    Filed: March 6, 2025
    Publication date: July 17, 2025
    Inventors: AmirAli TALASAZ, Helmy ELTOUKHY, Stefanie Ann Ward MORTIMER
  • Patent number: 12359245
    Abstract: The disclosure provides methods for processing nucleic acid populations containing different forms (e.g., RNA and DNA, single-stranded or double-stranded) and/or extents of modification (e.g., cytosine methylation, association with proteins). These methods accommodate multiple forms and/or modifications of nucleic acid in a sample, such that sequence information can be obtained for multiple forms. The methods also preserve the identity of multiple forms or modified states through processing and analysis, such that analysis of sequence can be combined with epigenetic analysis.
    Type: Grant
    Filed: July 11, 2024
    Date of Patent: July 15, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Andrew Kennedy, Stefanie Ann Ward Mortimer, Helmy Eltoukhy, AmirAli Talasaz, Diana Abdueva
  • Publication number: 20250223656
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Application
    Filed: March 24, 2025
    Publication date: July 10, 2025
    Inventor: AmirAli TALASAZ
  • Publication number: 20250197930
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Application
    Filed: March 4, 2025
    Publication date: June 19, 2025
    Inventors: AmirAli TALASAZ, Helmy ELTOUKHY, Stefanie Ann Ward MORTIMER
  • Publication number: 20250146085
    Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.
    Type: Application
    Filed: January 13, 2025
    Publication date: May 8, 2025
    Inventors: Stefanie Ann Ward MORTIMER, AmirAli TALASAZ, Darya CHUDOVA, Helmy ELTOUKHY
  • Patent number: 12286672
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: August 23, 2024
    Date of Patent: April 29, 2025
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
  • Patent number: 12281354
    Abstract: The present disclosure provides a method for monitoring residual disease in a subject. Generally, the method comprises determining a frequency of cancer mutations from a first sample obtained from a tumor biopsy from the subject; determining a frequency of the cancer mutations discovered in the first sample from a second sample comprising cell-free deoxyribonucleic acid (cfDNA) molecules that is obtained from the subject after the subject has undergone a course of treatment for cancer; and determining a presence or absence of cancer in the subject based on an analysis of the frequency of the cancer mutations from sequence data from the second sample, wherein adapters are ligated to at least 20% of the cfDNA molecules using more than a 10× molar excess of adapters relative to the cfDNA molecules in the population of cfDNA molecules.
    Type: Grant
    Filed: May 29, 2024
    Date of Patent: April 22, 2025
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Stefanie Ann Ward Mortimer
  • Patent number: 12258626
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Grant
    Filed: August 22, 2024
    Date of Patent: March 25, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Amirali Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
  • Patent number: 12252749
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: January 30, 2024
    Date of Patent: March 18, 2025
    Assignee: Guardant Health, Inc.
    Inventor: AmirAli Talasaz
  • Patent number: 12241128
    Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.
    Type: Grant
    Filed: February 14, 2024
    Date of Patent: March 4, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Stefanie Ann Ward Mortimer, Amirali Talasaz, Darya Chudova, Helmy Eltoukhy
  • Publication number: 20250051858
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Application
    Filed: October 29, 2024
    Publication date: February 13, 2025
    Inventor: AmirAli TALASAZ
  • Publication number: 20250002993
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Application
    Filed: August 22, 2024
    Publication date: January 2, 2025
    Inventors: AmirAli TALASAZ, Helmy ELTOUKHY, Stefanie Ann Ward MORTIMER
  • Publication number: 20240425915
    Abstract: Disclosed herein in are methods and systems for determining genetic variants (e.g., copy number variation) in a polynucleotide sample. A method for determining copy number variations includes tagging double-stranded polynucleotides with duplex tags, sequencing polynucleotides from the sample and estimating total number of polynucleotides mapping to selected genetic loci. The estimate of total number of polynucleotides can involve estimating the number of double-stranded polynucleotides in the original sample for which no sequence reads are generated. This number can be generated using the number of polynucleotides for which reads for both complementary strands are detected and reads for which only one of the two complementary strands is detected.
    Type: Application
    Filed: August 23, 2024
    Publication date: December 26, 2024
    Inventors: AmirAli TALASAZ, Helmy ELTOUKHY, Stefanie Ann Ward MORTIMER
  • Publication number: 20240409980
    Abstract: The disclosure provides methods for processing nucleic acid populations containing different forms (e.g., RNA and DNA, single-stranded or double-stranded) and/or extents of modification (e.g., cytosine methylation, association with proteins). These methods accommodate multiple forms and/or modifications of nucleic acid in a sample, such that sequence information can be obtained for multiple forms. The methods also preserve the identity of multiple forms or modified states through processing and analysis, such that analysis of sequence can be combined with epigenetic analysis.
    Type: Application
    Filed: July 11, 2024
    Publication date: December 12, 2024
    Inventors: Andrew KENNEDY, Stefanie Ann Ward MORTIMER, Helmy ELTOUKHY, AmirAli TALASAZ, DIANA ABDUEVA
  • Publication number: 20240409979
    Abstract: The disclosure provides methods for processing nucleic acid populations containing different forms (e.g., RNA and DNA, single-stranded or double-stranded) and/or extents of modification (e.g., cytosine methylation, association with proteins). These methods accommodate multiple forms and/or modifications of nucleic acid in a sample, such that sequence information can be obtained for multiple forms. The methods also preserve the identity of multiple forms or modified states through processing and analysis, such that analysis of sequence can be combined with epigenetic analysis.
    Type: Application
    Filed: July 11, 2024
    Publication date: December 12, 2024
    Inventors: Andrew KENNEDY, Stefanie Ann Ward MORTIMER, Helmy ELTOUKHY, AmirAli TALASAZ, DIANA ABDUEVA
  • Publication number: 20240345104
    Abstract: Provided herein are methods of detecting and quantifying target molecules associated with cell debris. Provided herein are also methods for determining the likelihood that a subject has a disease or condition, such as cancer.
    Type: Application
    Filed: November 10, 2023
    Publication date: October 17, 2024
    Inventors: AmirAli TALASAZ, Andrew KENNEDY
  • Patent number: 12116624
    Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.
    Type: Grant
    Filed: December 11, 2023
    Date of Patent: October 15, 2024
    Assignee: Guardant Health, Inc.
    Inventors: AmirAli Talasaz, Stefanie Ann Ward Mortimer
  • Patent number: 12116640
    Abstract: Disclosed herein are methods, compositions, and devices for use in the early detection of cancer. The methods include preparing cell-free nucleic acid molecules from a subject for sequencing, sequencing a panel of regions in the cell-free nucleic acid molecules, and detecting one or more markers that are indicative of a cancer.
    Type: Grant
    Filed: February 8, 2024
    Date of Patent: October 15, 2024
    Assignee: Guardant Health, Inc.
    Inventors: Stefanie Ann Ward Mortimer, AmirAli Talasaz, Darya Chudova, Helmy Eltoukhy
  • Patent number: D1077824
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: June 3, 2025
    Assignee: Guardant Health, Inc.
    Inventors: Helmy Eltoukhy, AmirAli Talasaz, Bahram Ghaffarzadeh Kermani, Nnamdi Ihuegbu